Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations By Ogkologos - October 22, 2025 219 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR Study Reinforces Treatment Idea for Cancer with Microsatellite Instability October 2, 2020 FDA Grants Accelerated Approval to Amivantamab-vmjw for Metastatic NSCLC with EGFR... May 28, 2021 Keto Molecule Offers Clue for Preventing Colorectal Cancer June 2, 2022 Genetic Cancer Screenings in Younger Women May Be Cost-Effective and Lead... November 26, 2020 Load more HOT NEWS OS Advantage of Gotistobart Over Docetaxel in Patients with anti-PD‑(L)1- and... FDA Grants Accelerated Approval to Talquetamab-tgvs for Relapsed or Refractory Multiple... How Your Oncology Nurse Can Help You During Cancer How to Get Started With Meditation During Cancer
